Shares of this BioPharma on a Tear as it Successfully Engineered a T-Cell From a Healthy Human Donor

By: Tomas Ronolski - AllPennyStocks.com News

Monday, June 10, 2024

CAR T-cell therapy has seen significant growth and much promise, as it provides targeted and personalized treatment for patients with certain types of cancer, particularly those that have not responded to traditional forms of treatment such as chemotherapy or radiation therapy. By reprogramming a patient's own immune cells to specifically target cancer cells, CAR T-cell therapy offers the potential for more effective and less toxic treatment options.

SOHM, Inc. (OTC PINK:SHMN) manufactures and markets generic drugs covering numerous treatment categories, announced in a press release today that preliminary data from a third-party user resulted in the firm’s ABBIE genome editing technology successfully engineering a T-cell from a healthy human donor and killed lung cancer cells in an experimental cancer model.

The data was presented at the 2024 AACR conference in San Diego. This breakthrough method for immunotherapy against cancer is normally made using a virus-based delivery system. However, the ABBIE system can be delivered as an mRNA or purified protein along with donor polynucleic acid and guide RNA without the use of a virus and is able to engineer lung cancer cell-killing CAR T-cells more efficiently.

Shares were trading up over 15 percent in heavy trading.

Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.